Biosimilar stocks Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
00:51
Feb 11
Feb 11
Biosimilar stocks benefit from US policy.
US drug-price pressure and PBM reform should steer demand toward cheaper biosimilars, so biosimilar-related companies should have a decent flow.
MED
About Biosimilar stocks Investor Commentary
Across the available history and selected sources, Buzzberg tracks Biosimilar stocks across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Jang Woo-jin.